[Abstract] A fundamental procedure for most modern biologists is the genetic manipulation of the organism under study. Although many different methods for editing bacterial genomes have been used in laboratories for decades, the adaptation of CRISPR/Cas9 technology to bacterial genetics has allowed researchers to manipulate bacterial genomes with unparalleled facility. CRISPR/Cas9 has allowed for genome edits to be more precise, while also increasing the efficiency of transferring mutations into a variety of genetic backgrounds. As a result, the advantages are realized in tractable organisms and organisms that have been refractory to genetic manipulation. Here, we describe our method for editing the genome of the bacterium Bacillus subtilis. Our method is highly efficient, resulting in precise, markerless mutations. Further, after generating the editing plasmid, the mutation can be quickly introduced into several genetic backgrounds, greatly increasing the speed with which genetic analyses may be performed.
)
Assemble 50 μl restriction digest reaction: 1x Cutsmart buffer (NEB), 2 μl BsaI-HF (20,000 U/ml; NEB), and 5 μg pPB41. Incubate reaction at 37 °C in an incubator for 3 to 6 h. Add 1 μl of calf intestinal phosphatase (CIP; 10,000 U/ml; NEB), and incubate at 37 °C for 1 h. Perform 1% agarose gel electrophoresis in 1x TAE buffer (see Recipes), followed by gel extraction of the digested plasmid.
Notes:
a. The plasmid pPB41 is typically used, but we also generated a derivative, pPB105, wherein the spectinomycin resistance cassette was replaced with a chloramphenicol resistance cassette (see Figure 1 ). Escherichia coli. Clones can be selected using LB agar plates (see Recipes) containing 100 μg/ml ampicillin or 100 μg/ml spectinomycin. Clones are verified via Sanger sequencing using oPEB253. Amplify pPB41 via PCR using Q5 DNA polymerase (NEB) and primers oPEB217 and oPEB218.
Note
Perform 1% agarose gel electrophoresis in 1x TAE buffer (see Recipes) followed by gel extraction. PCR product is stored at -20 °C until used. Gibson Assembly of editing plasmid using PCR products from A-C.
Notes
2. PCR amplify CRISPR/Cas9 using plasmid generated in step B1 ( Figure 4B) Amplify plasmid generated in step B1 (pPB43 in the example) via PCR using Q5 DNA polymerase (NEB) and primers oPEB232 and oPEB234. Perform 1% agarose gel Copyright 2272 electrophoresis in 1x TAE buffer (see Recipes) followed by gel extraction. PCR product is stored at -20 °C until used.
Note:
The PCR program used to amplify CRISPR/Cas9 is the same used in step B1 above. and Oligocalc (Kibbe, 2007 2. Several isolates (6) (7) (8) (9) (10) (11) (12) are established by colony purifying transformants ( Figure 5B) a. Colony purifying refers to restreaking isolated colonies three to four consecutive times for single colonies.
b. Single colonies from preceding step are re-streaked on LB agar plates for single colonies containing 100 μg/ml spectinomycin and incubated at 30 °C overnight in an incubator.
3. Cure isolates of plasmid ( Figure 5C )
Single colonies from preceding step are re-struck on LB agar plates for single colonies and incubated at 42-45 °C overnight.
We have an incubator set to 45 °C, but we have used 42 °C successfully. Inset shows wild-type mutS2 locus. B. After establishing isolates using colony purification, the isolates are cured of the editing plasmid. Inset depicts homology directed repair using the editing template on the plasmid. C. The final step is to verify loss of the editing plasmid and genotype isolates to verify the mutation was successfully introduced. Inset shows edited mutS2 locus.
Screen isolates for loss of plasmid
Single colonies from preceding step are re-streaked onto LB agar plates containing 100 μg/ml spectinomycin, and then onto LB agar plates for single colonies. Plates are incubated at 45 °C Copyright © 2017 The Authors; exclusive licensee Bio-protocol LLC.
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www.bio-protocol.org/e2272 2272 overnight in an incubator. If the isolates lost the plasmid, there would be no growth on the LB agar plates with spectinomycin.
Screen for intended mutation (Figure 6)
The isolates that were unable to grow on plates containing spectinomycin are further screened for the presence of the desired mutation. In the case of a point mutation, a primer can be designed to anneal at the point mutation ( Figure 6A ), or the genetic locus may be amplified using primers outside the editing template as done for a deletion (see below), followed by Sanger sequencing to verify the point mutation is present and no other mutations were introduced. In the case of a gene deletion, PCR primers that anneal outside of the recombination template within the genomic DNA are used to PCR amplify the genetic locus ( Figure 6B ). The migration of the PCR product will be faster relative to the product from wild-type locus. amplified PCR products using primers specific to the point mutation (H743A, for which we changed CAC→GCT) and the B. subtilis chromosome (left panel), and using primers specific to the editing plasmid (right panel). Of twelve isolates screened all were found to have the predicted point mutation, and two of twelve retained resistance to spectinomycin (asterisks).
The slow migrating band in the PY79 lane corresponds to nonspecific PCR amplification in the wild type background. The editing plasmid was detectable in spectinomycin resistant isolates, but not in the remaining ten. C. Agarose gel stained with ethidium bromide of PCR reactions using primers specific for deletion of four B. subtilis genes. Primers were designed outside of the isolates were found to be spectinomycin sensitive, and PCR genotyping of three isolates for each deletion found that all isolates tested had the intended deletion. Note that for the control reaction for ponA, the PCR product is faint because the amplicon is approximately 5 kb and the extension time of the PCR was 3 min, which is near the limit for complete extension for Q5 DNA polymerase; the other three control amplicons are no larger than 3.4 kb.
Save frozen stock of new strain
Separate LB cultures of at least two isolates that are confirmed to have the intended mutation are grown to an OD600 of approximately 1 to 1.5. A frozen stock is saved by adding glycerol to a final concentration of 20% in a cryo-vial. A cryo-vial cap is added to the lid and labeled appropriately. Cryo-vials are placed directly into a freezer at -80 °C.
Data analysis
There are two steps where data analysis is required for constructing a mutant strain. The first is assaying for loss of the editing plasmid using antibiotic sensitivity, and the second is to assay the genetic locus for the intended mutation using PCR genotyping. In order to determine if the isolates have been cured of the editing plasmid, six to twelve isolates are streaked onto LB agar plates with and without 100 μg/ml spectinomycin and grown overnight (see step C4 of the protocol). The isolates that do not grow on LB agar plates containing spectinomycin have been cured of the editing plasmid. The isolates that have been cured of the plasmid are further genotyped via PCR.
Data analysis of PCR genotyping will depend on the type of edit being introduced. For a deletion, PCR amplification of the genetic locus will result in a product with a migration that is faster than that of the wild-type locus, resulting in the PCR product appearing lower on the agarose gel. For an insertion, the PCR product would migrate slower than the wild-type product on the agarose gel. For a point mutation, there will be no change in the size of the PCR product. As a result, a mutation specific primer or Sanger sequencing must be used to confirm the correct genotype. For a mutation specific primer (see Figure 6B ), the PCR product will be present or absent. If the PCR product is present, that would indicate the mutation is present. If Sanger sequencing is used, the sequence of the mutation will be detected instead of the wild-type sequence. Ampicillin is added to a final concentration of 100 μg/ml
Chloramphenicol is added to a final concentration of 20 μg/ml for E. coli and 5 μg/ml for B. www.bio-protocol.org/e2272 
